Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes

JAMA

Volumn 311, Issue 22, 2014, Pages 2288-2296

  Roumie, Christianne L ^a,b   Greevy, Robert A ^a,b   Grijalva, Carlos G ^a,b   Hung, Adriana M ^a,b   Liu, Xulei ^a,b   Murff, Harvey J ^a,b   Elasy, Tom A ^a,b   Griffin, Marie R ^a,b  

^a Veterans Affairs Tennessee Valley Geriatric Research Education and Clinical Centers   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DIABETES MELLITUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; MALE; METFORMIN; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; RISK; STROKE; SULFONYLUREA COMPOUNDS; TREATMENT FAILURE;

EID: 84902216056     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.4312     Document Type: Article

References (40)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.
2. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008;371(9626):1753-1760. (Pubitemid 351697950)
3. Harrison LB, Adams-Huet B, Raskin P, Lingvay I. β-Cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care. 2012;35(7):1406-1412.
4. Alvarsson M, Sundkvist G, Lager I, et al. Effects of insulin vs glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up. Diabetes Obes Metab. 2008;10(5):421-429. (Pubitemid 351524289)
5. Centers for Disease Control and Prevention. Adults with diabetes by diabetes medication status: United States, 1997-2011. http://www.cdc.gov/ diabetes/statistics/meduse/fig1.htm. Accessed November 25, 2013.
6. Cohen FJ, Neslusan CA, Conklin JE, Song X. Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care. 2003;26(6):1847-1851. (Pubitemid 36929131)
7. Holden SE, Poole CD, Morgan CL, Currie CJ. Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin. BMJ Open. 2011;1(2):e000258.
8. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589.
9. Hung AM, Roumie CL, Greevy RA, et al. Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Kidney Int. 2012;81(7):698-706.
10. Arnold N, Hines D, Stroupe K. Comparison of VA Outpatient Prescriptions in the DSS Datasets and the PBM Database. Hines, IL: Edward Hines, Jr VA Hospital; 2006.
11. National Center for Health Statistics. International Classification of Diseases, Ninth Revision, Clinical Modification. Washington, DC: Public Health Service, US Dept of Health & Human Services; 1988.
12. Humensky J, Carretta H, de Groot K, Brown MM, Tarlov E, Hynes D. Service utilization of veterans dually eligible for VA and Medicare fee-for-service: 1999-2004. Medicare Medicaid Res Rev. 2012;2(3).
13. Hynes DM, Koelling K, Stroupe K, et al. Veterans' access to and use of Medicare and Veterans Affairs health care. Med Care. 2007;45(3):214-223.
14. McCarthy JF, Valenstein M, Kim HM, Ilgen M, Zivin K, Blow FC. Suicide mortality among patients receiving care in the Veterans Health Administration health system. Am J Epidemiol. 2009;169(8):1033-1038.
15. Greevy RA Jr, Huizinga MM, Roumie CL, et al. Comparisons of persistence and durability among three oral antidiabetic therapies using electronic prescription-fill data: the impact of adherence requirements and stockpiling. Clin Pharmacol Ther. 2011;90(6):813-819.
16. Niesner K, Murff HJ, Griffin MR, et al. Validation of VA administrative data algorithms for identifying cardiovascular disease hospitalization. Epidemiology. 2013;24(2):334-335.
17. Sohn MW, Arnold N, Maynard C, Hynes DM. Accuracy and completeness of mortality data in the Department of Veterans Affairs. Popul Health Metr. 2006;4:2.
18. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry. 2001;58(12):1161-1167. (Pubitemid 33121508)
19. Office of Minority Health, Department of Health and Human Services. Heart disease and African Americans. http://minorityhealth.hhs.gov/templates/content. aspx?ID=3018. Accessed February 19, 2014.
20. Yuan YC. Multiple Imputation for Missing Data: Concepts and New Development (Version 9.0). SAS; 2011.
21. Parsons L. Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques. http://www2.sas.com/proceedings/sugi26/p214-26.pdf. Accessed November 21, 2011.
22. D'Agostino R, Rubin D. Estimating and using propensity scores with partially missing data. J Am Stat Assoc. 2000;95(451):749-759.
23. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550-560. (Pubitemid 30660034)
24. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11(5):561-570. (Pubitemid 30660035)
25. Schneeweiss S, Glynn RJ, Tsai EH, Avorn J, Solomon DH. Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology. 2005;16(1):17-24. (Pubitemid 40239274)
26. Optmatch: Functions for Optimal Matching [computer program]. Version R package 0.9-1. 2010.
27. RItools: Randomization Inference Tools [computer program]. Version: R package 0.1-11. 2010.
28. Selby JV, Uratsu CS, Fireman B, et al. Treatment intensification and risk factor control: toward more clinically relevant quality measures. Med Care. 2009;47(4):395-402.
29. Kerr EA, Gerzoff RB, Krein SL, et al. Diabetes care quality in the Veterans Affairs Health Care System and commercial managed care: the TRIAD study. Ann Intern Med. 2004;141(4):272-281.
30. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
31. Gerstein HC, Miller ME, Byington RP, et al Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559. (Pubitemid 351831356)
32. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909.
33. Bonds DE, Miller ME, Dudl J, et al. Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: secondary analysis of the ACCORD clinical trial data. BMC Endocr Disord. 2012;12:5.
34. Gerstein HC, Bosch J, Dagenais GR, et al ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319-328.
35. Gamble JM, Simpson SH, Eurich DT, Majumdar SR, Johnson JA. Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes Obes Metab. 2010;12(1):47-53.
36. Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab. 2013;98(2):668-677.
37. Peyrot M, Rubin RR, Khunti K. Addressing barriers to initiation of insulin in patients with type 2 diabetes. Prim Care Diabetes. 2010;4(suppl 1):S11-S18.
38. Roumie CL, Huizinga MM, Liu X, et al. The effect of incident antidiabetic regimens on lipid profiles in veterans with type 2 diabetes: a retrospective cohort. Pharmacoepidemiol Drug Saf. 2011;20(1):36-44.
39. Roumie CL, Hung AM, Greevy RA, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med. 2012;157(9):601-610.
40. Roumie CL, Liu X, Choma NN, et al. Initiation of sulfonylureas versusmetformin is associated with higher blood pressure at one year. Pharmacoepidemiol Drug Saf. 2012;21(5):515-523.